HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare, Inc. senior vice president and Chief Nurse Executive Erica Rossitto reported her equity holdings as an officer of the company. She directly owns 9,149 shares of HCA common stock, along with restricted stock units covering 105 and 323 shares that convert into common stock as they vest beginning January 31, 2027. She also holds multiple stock appreciation rights grants over various share amounts, with exercise prices ranging from $81.96 to $482.53 and expiration dates between 2027 and 2036, many of which vest in four equal annual installments starting from specific past and future dates.
HCA Healthcare (HCA) CEO and director Samuel N. Hazen reported multiple open‑market sales of HCA common stock on February 3, 2026, at weighted average prices ranging from about $497.18 to $502.95 per share. After these sales, he directly held 32,276 shares of HCA common stock.
On February 4, 2026, Hazen reported a transfer of 1,045 shares at $498.35 per share to a trust under a power of substitution, in exchange for assets of equal value. The footnote states this was a change in the form of beneficial ownership and did not change the total number of HCA shares he may be deemed to beneficially own. Following the transfer, he directly held 31,231 shares and had additional indirect holdings through various trusts and a limited partnership, including 16,024 shares held by HD Trust and 813,320 shares held by an LP.
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026. A transaction coded “S” showed the disposition of 1,500 shares at $498.0901 per share. A second transaction coded “G” reported 4,050 shares at $0 per share. After these transactions, he directly owned 25,952.9017 shares of HCA common stock.
HCA Healthcare, Inc. shareholder plans Rule 144 sale of shares
A shareholder has filed a notice of intent to sell 1,500 shares of HCA Healthcare common stock through Merrill Lynch on the NYSE. The filing lists an aggregate market value of $747,135.15 and indicates an approximate sale date of February 3, 2026.
The shares were acquired on April 29, 2021 through the exercise of a stock appreciation right from HCA Healthcare, described as a compensatory payment. The notice states that the person signing does not know of any undisclosed material adverse information about HCA Healthcare’s current or prospective operations.
HCA Healthcare, Inc. common stock: a shareholder has filed a Form 144 to sell 42,877 common shares through Merrill Lynch on the NYSE, with an aggregate market value of 21483273.66.
The shares were acquired on 01/30/2026 by exercising a stock appreciation right granted by HCA Healthcare, Inc., with compensatory payment as consideration. The planned sale date is approximately 02/03/2026, and the filing notes 228,193,900 common shares outstanding.
HCA Healthcare, Inc. reported that its SVP & Controller, Christopher F. Wyatt, received a grant of stock appreciation rights on January 29, 2026. The award covers 2,560 stock appreciation rights with an exercise price of $482.53 per share.
These stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and are exercisable through January 29, 2036. Following this grant, Wyatt beneficially holds 2,560 derivative securities directly.
HCA Healthcare executive Michael R. McAlevey reported a new equity award. On January 29, 2026, he received 8,067 stock appreciation rights linked to HCA common stock, held as a direct beneficial owner.
The stock appreciation rights carry a $482.53 exercise price and vest in four equal annual installments beginning on January 29, 2027, giving this executive a long-term, performance-linked incentive tied to HCA Healthcare’s share price over time.
HCA Healthcare EVP and CFO Mike A. Marks received a new equity award in the form of stock appreciation rights. On January 29, 2026, he was granted 11,945 stock appreciation rights tied to HCA common stock at an exercise price of $482.53 per share. These rights vest in four equal annual installments beginning January 29, 2027 and expire January 29, 2036. Following this grant, he beneficially holds 11,945 derivative securities directly.
HCA Healthcare CEO Samuel N. Hazen reported several equity compensation moves. On January 29, 2026, he received 55,846 stock appreciation rights with an exercise price of $482.53 per share, which vest in four equal annual installments beginning on January 29, 2027.
On January 30, 2026, Hazen exercised 84,360 stock appreciation rights, acquiring 84,360 shares of common stock at $81.96 per share. To cover tax obligations, 41,483 shares were surrendered at a value of $488.27 per share, leaving 75,153 shares of common stock held directly. He also reports additional indirect ownership through several trusts and an LP.
HCA Healthcare EVP and COO Jon M. Foster reported a grant of 11,945 stock appreciation rights (SARs) on HCA common stock at an exercise price of $482.53 per share. These SARs become exercisable in four equal annual installments beginning on January 29, 2027 and expire on January 29, 2036. The filing also lists indirect holdings of HCA common stock held through several trusts, including JMF Trust, LCF Trust, JMF Family Trust, and a 2025 GRAT.